PL2323633T3 - Stabilna kompozycja farmaceutyczna dla zoptymalizowanego dostarczania inhibitora zaczepu HIV - Google Patents

Stabilna kompozycja farmaceutyczna dla zoptymalizowanego dostarczania inhibitora zaczepu HIV

Info

Publication number
PL2323633T3
PL2323633T3 PL09792207T PL09792207T PL2323633T3 PL 2323633 T3 PL2323633 T3 PL 2323633T3 PL 09792207 T PL09792207 T PL 09792207T PL 09792207 T PL09792207 T PL 09792207T PL 2323633 T3 PL2323633 T3 PL 2323633T3
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
stable pharmaceutical
optimized delivery
hiv attachment
attachment inhibitor
Prior art date
Application number
PL09792207T
Other languages
English (en)
Polish (pl)
Inventor
Jonathan R Brown
Helen Toale
Andrew B Dennis
Peter Timmins
Original Assignee
Viiv Healthcare Uk No 4 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 4 Ltd filed Critical Viiv Healthcare Uk No 4 Ltd
Publication of PL2323633T3 publication Critical patent/PL2323633T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/062—Organo-phosphoranes without P-C bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
PL09792207T 2008-09-04 2009-09-03 Stabilna kompozycja farmaceutyczna dla zoptymalizowanego dostarczania inhibitora zaczepu HIV PL2323633T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9413108P 2008-09-04 2008-09-04
EP09792207A EP2323633B1 (en) 2008-09-04 2009-09-03 Stable pharmaceutical composition for optimized delivery of an hiv attachment inhibitor
PCT/US2009/055820 WO2010028108A2 (en) 2008-09-04 2009-09-03 Stable pharmaceutical composition for optimized delivery of an hiv attachment inhibitor

Publications (1)

Publication Number Publication Date
PL2323633T3 true PL2323633T3 (pl) 2012-08-31

Family

ID=41726353

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09792207T PL2323633T3 (pl) 2008-09-04 2009-09-03 Stabilna kompozycja farmaceutyczna dla zoptymalizowanego dostarczania inhibitora zaczepu HIV

Country Status (16)

Country Link
US (2) US20100056540A1 (enExample)
EP (1) EP2323633B1 (enExample)
JP (1) JP5638527B2 (enExample)
CN (1) CN102143739B (enExample)
AT (1) ATE550016T1 (enExample)
CA (1) CA2735008C (enExample)
CY (1) CY1112816T1 (enExample)
DK (1) DK2323633T3 (enExample)
ES (1) ES2383149T3 (enExample)
HR (1) HRP20120441T1 (enExample)
NL (1) NL301118I2 (enExample)
PL (1) PL2323633T3 (enExample)
PT (1) PT2323633E (enExample)
SI (1) SI2323633T1 (enExample)
SM (1) SMT201200029B (enExample)
WO (1) WO2010028108A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248139B2 (en) * 2011-12-21 2016-02-02 Bristol-Myers Squibb Company Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
US5124327A (en) * 1991-09-06 1992-06-23 Merck & Co., Inc. HIV reverse transcriptase
JP2686215B2 (ja) * 1993-04-28 1997-12-08 信越化学工業株式会社 徐放性錠剤
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20020061892A1 (en) * 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US6825201B2 (en) * 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
US20040063744A1 (en) * 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060167044A1 (en) * 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
US7601715B2 (en) * 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents

Also Published As

Publication number Publication date
CA2735008A1 (en) 2010-03-11
WO2010028108A2 (en) 2010-03-11
SMT201200029B (it) 2012-09-07
ES2383149T3 (es) 2012-06-18
PT2323633E (pt) 2012-05-29
CY1112816T1 (el) 2016-02-10
CN102143739A (zh) 2011-08-03
DK2323633T3 (da) 2012-07-09
NL301118I1 (enExample) 2021-07-23
US20150158891A1 (en) 2015-06-11
ATE550016T1 (de) 2012-04-15
JP2012502042A (ja) 2012-01-26
US20100056540A1 (en) 2010-03-04
EP2323633A2 (en) 2011-05-25
JP5638527B2 (ja) 2014-12-10
SI2323633T1 (sl) 2012-07-31
CA2735008C (en) 2016-11-29
CN102143739B (zh) 2014-12-17
HRP20120441T1 (hr) 2012-06-30
WO2010028108A3 (en) 2010-09-02
NL301118I2 (nl) 2022-02-22
EP2323633B1 (en) 2012-03-21

Similar Documents

Publication Publication Date Title
NZ597203A (en) Novel phenylimidazole derivative as pde10a enzyme inhibitor
MX2009001062A (es) Agonistas de ep2.
GB2459393B (en) Novel capsule formulation for the proton pump inhibitor omeprazole
EP2379060A4 (en) PHARMACEUTICAL FORMULATIONS WITH EXTENDED RELEASE
MY184008A (en) Aryl pyridine as aldosterone synthase inhibitors
NO20082477L (no) Krystallinske former av 1-benzoyl-4-[2-[4-metoksy-7-(3-metyl-1H-1,2,4-triazol-1-yl-1-[(fosfonooksy)metyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioksoetyl]-piperazin
GEP20125415B (en) Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
MX2011012199A (es) Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona.
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
WO2008152014A3 (en) 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
NZ592314A (en) Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine
PT2049480E (pt) Derivados de 2-arilindole como inibidores da mpges-i
NZ592927A (en) PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS such as pimobendan FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
TNSN08369A1 (en) Benzimidazole derivatives
NL301118I1 (enExample)
WO2008009802A3 (fr) Medicaments comprenant un inhibiteur des alpha-mannosidases de classe i pour le traitement des sarcoglycanopathies
MX2008000342A (es) Formulacion de fentanilo que contiene un aceite esencial.
UA94953C2 (en) Ep2 agonists
MX2009013054A (es) Composicion farmaceutica que comprende un sustrato y un revestimiento que contiene un ingrediente activo y alcohol polivinilico.
PL2089030T3 (pl) Środek do zapobiegania lub leczenia uzależnienia od alkoholu lub uzależnienia od narkotyków
WO2005065682A3 (en) Rabeprazole containing formulation
TN2011000612A1 (en) Novel phenylimidazole derivative as pde 10a enzyme inhibitor
HK1137147B (en) Novel capsule formulation for the proton pump inhibitor omeprazole
TW200833325A (en) Pharmaceutical composition comprising ascorbic acid